Related Experiment Video

Updated: Jul 5, 2026

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

Parvalbumin isoforms for enhancing cardiac diastolic function

Wang Wang1, Joseph M Metzger

  • 1Department of Molecular and Integrative Physiology, University of Michigan Medical School, 1301 E. Catherine St., 7727 Medical Science II, Ann Arbor, MI 48109-0622, USA.

Cell Biochemistry and Biophysics
|May 7, 2008
PubMed

Insights

Parvalbumin (Parv) gene transfer accelerates myocardial relaxation and corrects diastolic dysfunction in diastolic heart failure (DHF). This approach targets calcium handling defects, offering a novel therapeutic strategy for DHF patients.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Genetic Therapeutics

Background:

  • Diastolic heart failure (DHF) affects nearly half of heart failure patients with preserved ejection fraction.
  • Impaired myocardial relaxation and ventricular filling in DHF are linked to defective intracellular calcium (Ca2+) handling.
  • Current therapeutic strategies for DHF remain limited.

Purpose of the Study:

  • To review the rationale and development of parvalbumin (Parv) gene transfer for DHF.
  • To discuss the impact of Parv isoforms on cardiac Ca2+ handling and function.
  • To explore Parv as a therapeutic target for diastolic dysfunction.

Main Methods:

  • Review of existing literature on parvalbumin and diastolic heart failure.
  • Analysis of genetic manipulation strategies involving Ca2+ handling proteins.
  • Discussion of in vitro and in vivo studies on parvalbumin's effects.

Main Results:

  • Ectopic expression of parvalbumin accelerates myocardial relaxation.
  • Parvalbumin acts as a 'delayed' Ca2+ buffer, promoting Ca2+ transient decay.
  • Parv corrects diastolic dysfunction in an energy-independent manner.

Conclusions:

  • Parvalbumin gene transfer represents a promising therapeutic approach for DHF.
  • Understanding Parv isoform-specific effects is crucial for optimizing treatment.
  • This strategy aims to alleviate diastolic dysfunction by improving Ca2+ handling.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...